| Risperidone LAI Group n = 26 | Oral Medication Group n = 24 | Total group n = 50 | ||
---|---|---|---|---|---|
Demographic variables | |||||
Age, years | 36.8 (10.81) | 42.58 (10.71) | 39.6 (11.04) | ||
Gender | 73% Male, | 70% Male | 72% Male, | ||
Ethnicity | 77% White, | 54% White, | 66% White, | ||
Substance use/abuse | 46% No, | 58% No | 52% No, | ||
Clinical symptoms | |||||
 | Median (IQR) | Median (IQR) | Total Group | ||
 | Baseline | Follow-up | Baseline | Follow-up | Baseline |
PANSS total | 80 (67–91) | 71.5 (51–88) | 71 (62.5-86) | 60 (41–86) | 80 (65–90) |
PANSS Positive | 16.5 (14–26) | 15.5 (12–22) | 17 (13–21) | 15 (10–21) | 18 (13–22) |
PANSS Negative | 21 (14–25) | 17 (13–21) | 20 (17.5-25) | 16 (11–22) | 21.5 (17–27) |
CGI-Severity | 4.5 (4–5) | 3.5 (3–5) | 4 (3–5) | 3 (2–4) | 4 (3–5) |
AIMS | 0 (0–1) | 0 (0–0) | 1 (0–3.5) | 0 (0–1) | 0 (0–3) |
Quality of life | |||||
AQOL Illness | 0.42 (0.17-0.52) | 0.52 (0.42-0.64) | 0.36 (0.14-0.59) | 0.42 (0.26-0.53) | 0.40 (0.15-0.52) |
AQOL Activities Daily Life | 0.78 (0.62-0.0.86) | 0.88 (0.78-1.00) | 1.00 (0.78-1.00) | 1.00 (0.79-1.00) | 0.79 (0.62-1.00) |
AQOL Social | 0.70 (0.27-0.82) | 0.74 (0.35-0.88) | 0.69 (0.24-0.88) | 0.74 (0.35-0.94) | 0.69 (0.24-0.83) |
AQOL Physical | 1.00 (0.82-1.00) | 0.93 (0.82-1.00) | 1.00 (0.94-1.00) | 1.00 (0.94-1.00) | 1.00 (0.88-1.00) |
AQOL Psychological | 0.87 (0.73-0.91) | 0.91 (0.73-0.93) | 0.87 (0.67-0.93) | 0.95 (0.83-1.00) | 0.87 (0.70-0.93) |
 | Mean (sd) | Mean (sd) | Mean (sd) | Mean (sd) | Mean (sd) |
Working Alliance (prorated) | 48.33 (33.10) | 27.30 (27.90) | 45.97 (31.64) | 49.30 (35.32) | 48.20 (32.08) |